Hostname: page-component-745bb68f8f-d8cs5 Total loading time: 0 Render date: 2025-01-13T01:04:46.280Z Has data issue: false hasContentIssue false
  • English
  • Français

Anti-Glutamate Therapy in Amyotrophic Lateral Sclerosis: A Trial Using Lamotrigine

Published online by Cambridge University Press:  18 September 2015

Eisen Andrew ,
Stewart Heather ,
Schulzer Michael  and
Cameron Donald
Eisen Andrew*
Affiliation:
Neuromuscular Diseases Unit, The Vancouver General Hospital and The University of British Columbia, Vancouver
Stewart Heather*
Affiliation:
Neuromuscular Diseases Unit, The Vancouver General Hospital and The University of British Columbia, Vancouver
Schulzer Michael*
Affiliation:
Neuromuscular Diseases Unit, The Vancouver General Hospital and The University of British Columbia, Vancouver
Cameron Donald*
Affiliation:
Neuromuscular Diseases Unit, The Vancouver General Hospital and The University of British Columbia, Vancouver
*
The Neuromuscular Diseases Unit, The Vancouver General Hospital, 855 West 12th Avenue, Vancouver, British Columbia, Canada V5Z IM9
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Glutamate excitotoxicity is implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). We report the results of a double blind, placebo controlled, trial using 100 mg of oral daily lamotrigine (3,5-diamino-6-(2,3 dichlorophenyl)-l,2,4-triazine) which inhibits glutamate release. 67 patients were entered and at trial termination of 1.5 years 15 had withdrawn (9 active and 6 placebo) and 12 had died (6 active and 6 placebo). Mean age at entry was 57.5 years for the active and 58.6 years for the placebo groups. Patients were seen at 3 monthly intervals and scored according to neurological deficit based upon age of onset, bulbar and respiratory involvement, ambulation and functional disability. The mean change in clinical scores for the active versus placebo groups over the trial period was 7.1 ± 3.3 and 9.0 ± 3.3 respectively (0.05 < p < 0.10). Changes in cortical threshold and MEP/CMAP ratios to magnetic stimulation also did not differ significantly between the two groups. We conclude that lamotrigine in the doses administered does not alter the course of ALS.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 20 , Issue 4 , November 1993 , pp. 297 - 301
Copyright
Copyright © Canadian Neurological Sciences Federation 1993

References

REFERENCES

1.Choi, DW.Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988; 1: 623–634.CrossRefGoogle ScholarPubMed
2.Plaitakis, A.Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: a hypothesis. Ann Neurol 1990; 28: 3–8.CrossRefGoogle ScholarPubMed
3.Young, AB.What’s the excitement about excitatory amino acids in amyotrophic lateral sclerosis? Ann Neurol 1990; 28: 9–11.CrossRefGoogle ScholarPubMed
4.Rothstein, JD, Tsai, G, Kuncl, RW, et al.Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28: 18–25.CrossRefGoogle ScholarPubMed
5.Weiss, JH, Choi, DW.Differential vulnerability to excitatory amino acid-induced toxicity and selective neuronal loss in neurodegenerative diseases. Can J Neurol Sci 1991; (Suppl 3): 18: 394–397.CrossRefGoogle ScholarPubMed
6.Rothstein, JD, Kuncl, RW, Chaudhry, V, et al.Excitatory amino acids in amyotrophic lateral sclerosis: an update. Ann Neurol 1991; 30: 224–225.CrossRefGoogle ScholarPubMed
7.Brodie, MJ.Drug profiles: lamotrigine. Lancet 1992; 339: 1397–1400.CrossRefGoogle Scholar
8.Rowland, LP.Ten central themes in a decade of ALS research. In: Rowland, LP, ed. Advances in Neurology, Vol 56: Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases. Raven Press Ltd., 1991: 3–23.Google Scholar
9.Parry, GJ, Clark, S.Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 1988; 11: 103–107.CrossRefGoogle ScholarPubMed
10.Pestronk, A.Invited review: motor neuronopathies, motor neuron disorders, and antiglycolipid antibodies. Muscle Nerve 1991; 14: 927–936.Google Scholar
11.Daube, JR.Electrophysiological studies in the diagnosis and prognosis of motor neuron diseases. Neurol Clin 1985; 3: 473–493.CrossRefGoogle ScholarPubMed
12.Eisen, A.Transcranial magnetic stimulation in amyotrophic lateral sclerosis and some other disorders involving the pyramidal pathways. In: Lissens, MA, ed. Clinical Applications of Magnetic Transcranial Stimulation. Leuven: Peeters Press, 1992; 91–105.Google Scholar
13.Hufnagel, A, Elger, CE, Marx, W, Ising, A.Magnetic stimulationmotor-evoked potentials in epilepsy: effects of the disease and anticonvulsant medications. Ann Neurol 1990; 28: 680–686.CrossRefGoogle Scholar
14.Caramia, MD, Cicinelli, P, Paradiso, C., Marioenzi, R, et al.Excitability changes of muscular responses to magnetic brain stimulation in patients with central motor disorders. Electroencephalogr Clin Neurophysiol 1991; 81: 243–250.CrossRefGoogle ScholarPubMed
15.Wassermann, EM, McSahane, LM, Hallett, M, Cohen, LG.Non invasive mapping of muscle representations in human motor cortex. Electroencephalogr Clin Neurophysiol 1992; 85: 1–8.CrossRefGoogle Scholar
16.Eisen, A, Shtybel, W.Clinical experience with transcranial magnetic stimulation. Muscle Nerve 1990; 13: 995–1011.CrossRefGoogle ScholarPubMed
17.Eisen, A, Pant, B, Stewart, H.Cortical excitability in amyotrophic lateral sclerosis: a clue to pathogenesis. Can J Neurol Sci 1993; 20: 11–16.CrossRefGoogle ScholarPubMed
18.Whitehead, J.The Design and Analysis of Sequential Clinical Trials. Second Edition. New York; Ellis Horwood, 1992; 74–136.Google Scholar
19.Brooks, BR, Sufit, RL, DePaul, R, et al.Design of clinical therapeutic trials in amyotrophic lateral sclerosis. In: Rowland, LP, ed. Advances in Neurology, Vol 56: Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases. Raven Press Ltd, 1991; 521 –546.Google ScholarPubMed
20.Eisen, A, Schulzer, M, MacNeil, M, Pant, B, et al. Duration of amyo-trophic lateral sclerosis is age dependent. Muscle & Nerve 1993; 16: 27–32.CrossRefGoogle Scholar
21.Rothstein, JD, Martin, LJ, Kuncl, RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992; 326: 1464–1468.CrossRefGoogle ScholarPubMed
22.Choi, DW.Amyotrophic lateral sclerosis and glutamate – too much of a good thing? N Engl J Med 1992; 326: 1493–1494.CrossRefGoogle ScholarPubMed
23.Piaitakis, A, Smith, J, Mandeli, J, Yahr, MD.Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis. Lancet 1988; 1: 1015–1018.CrossRefGoogle Scholar
24.Testa, D, Caraceni, T, Fetoni, V.Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis. J Neurol 1989; 236: 445–447.CrossRefGoogle ScholarPubMed
25.Applebaum, JS, Salazar-Grueso, F, Richman, JG, et al. Dextro-methorphan in the treatment of ALS: a pilot study. Neurology 1991; 41(Suppl 1): 393p.Google Scholar
26.Plaitakis, A, Constantakakis, E, Smith, J.The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann Neurol 1988; 24: 446–449.CrossRefGoogle ScholarPubMed
27.Steinberg, GK.Effects of dextromethorphan on regional cerebral blood flow in focal cerebral ischemia. J Cereb Blood Flow Metab 1991; 11: 803–809.Google Scholar
28.Leander, JD.Evaluation of dextromethorphan and carbetapentane as anticonvulsants and N-methyl-D-aspartic acid antagonists in mice. Epilepsy Res 1989; 4: 28–33.CrossRefGoogle ScholarPubMed
29.Fisher, RS, Cysyk, BJ, Lesser, RP, et al. Dextromethorphan for treatment of complex partial seizures. Neurology 1990; 40: 547–549.CrossRefGoogle ScholarPubMed
30.Walker, FO, Hunt, VP.An open label trial of dextromethorphan in Huntingtons’s disease. J Clin Neuropharmacol 1989; 12: 322–330.CrossRefGoogle Scholar
31.Meier, DH, Schott, KJ. Free amino acid pattern of cerebrospinal fluid in amyotrophic lateral sclerosis. Acta Neurol Scand 1988; 77: 50–53.CrossRefGoogle ScholarPubMed
32.Cottell, E, Hutchinson, M, Simon, J, Harrington, MG.Plasma gluta mate levels in normal subjects and in patients with amyotrophic lateral sclerosis. Biochem Soc Trans 1990; 18: 283p.CrossRefGoogle Scholar
33.Perry, TL, Krieger, C, Hansen, S, Eisen, A.Amyotrophic lateral scie-rosis: amino acid levels in plasma and cerebrospinal fluid. Ann Neurol 1990; 28: 12–17.CrossRefGoogle ScholarPubMed
34.Iwasaki, Y, Ikeda, K, Kinoshita, M.Plasma amino acid levels in patients with amyotrophic lateral sclerosis. J Neurol Sci 1992; 107: 219–222.CrossRefGoogle ScholarPubMed
35.Pant, B, Eisen, A, Stewart, H.Some fasciculations in ALS result from corticomotoneuronal drive. Neurology 1992; 42 (Suppl 3): 468p.Google Scholar
36.Rosen, D, Siddique, T, Patterson, D, Figlewicz, DA, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59–62.CrossRefGoogle ScholarPubMed
37.Eubanks, JH, Puranam, RS, Kleckner, NW, Bettler, B, et al. The gen encoding the glutamate receptor subunit GluR5 is located on human chromosome 2 lq21.1-22.1 in the vicinity of the gene for familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 1993; 90: 178–182.CrossRefGoogle Scholar